We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Guidance Sets Parameters for Pediatric Trials of PAH Meds
EMA Guidance Sets Parameters for Pediatric Trials of PAH Meds
March 14, 2012
Relevant endpoints for clinical trials of drugs to treat pulmonary arterial hypertension (PAH) in children are exercise, time to clinical worsening and hemodynamic parameters, according to a European Medicines Agency (EMA) final guideline.